Statin tolerability: In defence of placebo-controlled trials

European Journal of Preventive Cardiology

Volumn 23, Issue 8, 2016, Pages 891-896

  Tobert, Jonathan A ^a   Newman, Connie B ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

nocebo effect; PCSK9 antibody; re challenge; Statin intolerance; statin muscle effects; statin side effects; stopping statins

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; CREATINE KINASE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; SIMVASTATIN; LIPID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY ATHEROSCLEROSIS; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; MUSCLE FUNCTION; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; OBSERVATIONAL STUDY; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RHABDOMYOLYSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; BLOOD; CARDIOVASCULAR DISEASE; COMPLICATION; DRUG TOLERANCE; HYPERCHOLESTEROLEMIA;

CARDIOVASCULAR DISEASES; DRUG TOLERANCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPIDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84964691274     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487315602861     Document Type: Article

References (40)

1. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-1818.
2. JBS3 Board. Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 2014; 100: ii1-ii67.
3. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681.
4. Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012; 308: 2497-2506.
5. Moriarty PM, Jacobson TA, Bruckert E, et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol 2014; 8: 554-561.
6. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: Impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015; 36: 1012-1022.
7. Grundy S, Brown WV,. From the editor: An interview with Dr. Scott Grundy. J Clin Lipidol 2014; 8: 1-8.
8. Maningat P, Breslow JL,. Needed: Pragmatic clinical trials for statin-intolerant patients. N Engl J Med. 2011; 365: 2250-2251.
9. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: A systematic overview of randomized clinical trials. Circulation 2006; 114: 2788-2797.
10. Neuvonen PJ, Niemi M, Backman JT,. Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80: 565-581.
11. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
12. Expert Dyslipidemia Panel of the International Atherosclerosis Society. An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-full report. J Clin Lipidol 2014; 8: 29-60.
13. The Scandinavian Simvastatin Survival Study Group. Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. Am J Cardiol 1993; 71: 393-400.
14. Tobert JA,. Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2003; 2: 517-526.
15. Lindgren P, Jonsson B,. Cost-effectiveness of statins revisited: Lessons learned about the value of innovation. Eur J Health Econ 2012; 13: 445-450.
16. Newman CB, Tobert JA,. Statin intolerance: Reconciling clinical trials and clinical experience. JAMA 2015; 313: 1011-1012.
17. Joy TR, Monjed A, Zou GY, et al. N-of-1 (single-patient) trials for statin-related myalgia. Ann Int Med 2014; 160: 301-310.
18. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-The PRIMO Study. Cardiovasc Drugs Ther 2005; 19: 403-414.
19. Cohen JD, Brinton EA, Ito MK, et al. Understanding Statin Use in America and Gaps in Patient Education (USAGE): An internet-based survey of 10,138 current and former statin users. J Clin Lipidol 2012; 6: 208-215.
20. Desai CS, Martin SM, Blumenthal RS,. Non-cardiovascular effects associated with statins. BMJ 2014; 349: g3743-g3743.
21. Mancini GB, Baker S, Bergeron J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol 2011; 27: 635-662.
22. Armitage J, Baigent C, Collins R,. Misrepresentation of statin safety evidence. Lancet 2014; 384: 1263-1264.
23. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: A cohort study. Ann Intern Med 2013; 158: 526-534.
24. Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: The Cleveland Clinic experience. Am Heart J 2013; 166: 597-603.
25. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010; 376: 1658-1669.
26. Armitage J, Bowman L, Collins R, et al. Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people. BMC Clin Pharmacol 2009; 9: 6-6. doi:10.1186/1472-6904-9-6.
27. Amarenco P, Bogousslavsky J, Callahan A, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-559.
28. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742.
29. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. JAMA 2011; 305: 2556-2564.
30. Finegold JA, Manisty CH, Goldacre B, et al. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol 2014; 21: 464-474.
31. Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation 2013; 127: 96-103.
32. Thompson PD. The Effect of Statin Medications on Muscle Performance (The STOMP Study). ClinicalTrials.gov identifier NCT00609063, https://clinicaltrials.gov/ct2/show/NCT00609063?term=STOMP&rank=3 (2012, accessed 5 May 2015).
33. Pocock SJ, Geller NL, Tsiatis AA,. The analysis of multiple endpoints in clinical trials. Biometrics 1987; 43: 487-498.
34. Ballard KD, Taylor BA, Thompson PD,. Statin-associated muscle injury. Eur J Prev Cardiol 2015; 22: 1161-1161.
35. Keech A, Collins R, MacMahon S, et al. Three-year follow-up of the Oxford Cholesterol Study: Assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 1994; 15: 255-269.
36. Häuser W, Hansen E, Enck P,. Nocebo phenomena in medicine: Their relevance in everyday clinical practice. Dtsch Arztebl Int 2012; 109: 459-465.
37. Bingel U,. Avoiding nocebo effects to optimize treatment outcome. JAMA 2014; 312: 693-694.
38. Golden J and Roberts M. Clinical Briefing Document, p 23. US Food and Drug Administration Center for Drug Evaluation and Research, The Endocrinologic and Metabolic Drugs Advisory Committee Meeting, 9 June 2015 Briefing Document, BLA 125559, Praluent (alirocumab) injection, http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm449865.pdf (2015, accessed 6 June 2015).
39. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-2397.
40. Pollack A. New drug sharply Lowers Cholesterol, but It's Costly. The New York Times, http://www.nytimes.com/2015/07/25/business/us-approves-drug-that-can-sharply-lower-cholesterol-levels.html (2015, accessed 27 July 2015).